Evidence map›Paper›PMID 34613491›Full record

ReviewCurrent treatment options in oncology2021

Targeted Therapy for BRAF Mutant Brain Tumors.

Appaji Rayi, Iyad Alnahhas, Shirley Ong, Pierre Giglio, Vinay K Puduvalli

Open access · hybridAbstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Appaji RayiDepartment of Neurology, Charleston Area Medical Center, Charleston, WV, USA.
Iyad AlnahhasDivision of Neuro-Oncology, Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.
Shirley OngDivision of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Pierre GiglioDivision of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Vinay K PuduvalliDepartment of Neuro-Oncology, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 431, Houston, TX, 77030, USA. vpuduval@mdanderson.org.
The Ohio State University Wexner Medical Center · USCharleston Area Medical Center · USThe University of Texas MD Anderson Cancer Center · USThomas Jefferson University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementMolecular heterogeneity has confounded attempts to target individual pathways in brain tumors. However, gliomas with BRAF mutations have been identified as being uniquely vulnerable to targeted therapies. Such mutations are predominantly seen in brain tumors of the adolescent and young adult population. Given that accurate and timely identification of such mutations is essential for offering appropriate treatment, treatment centers should offer both immunohistochemical and sequencing methods for detection of these mutations to guide treatment. Additional studies of these tumors at recurrence would also allow identification of breakthrough resistance mechanisms that may also be targetable for treatment. Due to the relative rarity of these tumors, multicenter collaborative studies will be essential in achieving long term control of these tumors.

Indexed as

Biomarkers, TumorMolecular Targeted TherapyMutationAllelesAmino Acid SubstitutionBrain NeoplasmsClinical Trials as TopicDiagnosis, DifferentialDisease ManagementDisease SusceptibilityDrug Resistance, NeoplasmGenetic Predisposition to DiseaseGenotypeHumansPrognosisProtein Kinase InhibitorsBiomarkers, TumorBRAF protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins B-raf

Identifiers

PMID34613491
OpenAlexW3201908133

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.